Medical Science News

RSS

CHOC Children's receives royalty-free research license to certain StemCells' patents

StemCells, Inc. and the Children's Hospital of Orange County ("CHOC Children's") announced today that they have entered into an agreement that provides CHOC Children's with a royalty-free research license to certain of StemCells' patents. This license authorizes CHOC Children's to proliferate, maintain and use human neural stem cells for non-commercial purposes.

4 Jun 2010

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

Researchers at Mount Sinai School of Medicine have developed a new gene therapy that is safe and effective in reversing advanced heart failure. SERCA2a (produced as MYDICAR-) is a gene therapy designed to stimulate production of an enzyme that enables the failing heart to pump more effectively.

4 Jun 2010

New pricing of $19,500 set for Illumina's individual genome sequencing service

Illumina, Inc. today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

From Illumina, Inc. 4 Jun 2010

New synthetic Petri dish harvests human embryonic stem cells

A new synthetic Petri dish coating could overcome a major challenge to the advancement of human embryonic stem cell research, say University of Michigan researchers.

3 Jun 2010

New approach to treat RA can change lives of millions of patients: Research

Portuguese scientists have just published a revolutionary new approach to treat rheumatoid arthritis (RA) which, if translated to humans, can change the way we treat autoimmunity (and so diseases like RA but also diabetes and MS) and, with it, the lives of millions of patients.

3 Jun 2010

X+ allele of APOB gene is important risk factor of gallstone formation after gastrectomy: Research

The cause of higher incidence of gallstone after radical gastrectomy still remains unknown. Almost all previous studies have attributed gallstone formation to gallbladder motility disorder after gastrectomy, But this theory cannot completely explain it. Is there any other risk factor of gallstone formation after gastrectomy?

3 Jun 2010

U-M researchers one step closer to discovering why certain diseases affect specific organs

Why do some diseases affect only specific organs, leaving others invulnerable? Researchers from the University of Michigan have found neural tissue contains imbalanced levels of proteins, which may explain the brain's susceptibility to a debilitating childhood movement disorder.

3 Jun 2010

Life Technologies, DKFZ collaborate to create National High-Throughput Sequencing Center

Life Technologies Corporation and the German Cancer Research Center (Deutsches Krebsforschungszentrum or DKFZ) today announced their collaboration to create the National High-Throughput Sequencing Center. This exclusive partnership will create the largest sequencing facility in Germany and the first national sequencing center in Europe dedicated to systems biology.

3 Jun 2010

Researchers discover relationship between DNA methylation and positioning of nucleosomes

A previously unknown pattern in DNA methylation - an event that affects cell function by altering gene expression - has been uncovered for the first time by stem cell researchers at UCLA, a finding that could have implications in preventing some cancers and correcting defects in human stem cell lines.

3 Jun 2010

Researchers describe chain of molecular events that increase one's risk of skin cancer

As people head to the beach this summer, very few if any, really know how likely they are to develop skin cancer from their outdoor fun. That's about to change, thanks to a new discovery by an international team of scientists that makes it possible for doctors to access people's personal risk for skin cancer.

3 Jun 2010

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Here's another reason to breast feed your baby: Canadian researchers have discovered how a probiotic found in breast milk reduces or eliminates painful cramping in the gut. In a new research report published online in the FASEB Journal, these scientists use mice to show that a specific strain of Lactobacillus reuteri decreases the force of muscle contractions in the gut within minutes of exposure.

3 Jun 2010

Discovery provides new therapeutic target to prevent brain function loss

Researchers at Mount Sinai School of Medicine have found that certain types of specializations on nerve cells called "spines" are depleted as a person ages, causing cognitive decline in the part of the brain that mediates the highest levels of learning. These spines receive an important class of synapses that are involved with the process of learning.

3 Jun 2010

Meditation-based therapies benefit patients with chronic pain

People who meditate regularly find pain less unpleasant because their brains anticipate the pain less, a new study has found.

2 Jun 2010

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

An enzyme implicated in osteoporosis, arthritis, atherosclerosis and cancer metastasis -- cathepsin K -- eluded reliable detection in laboratory experiments in the past. Now, a research team at the Georgia Institute of Technology has developed an assay that reliably detects and quantifies mature cathepsin K using a technique called gelatin zymography.

2 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

2 Jun 2010

Predictive biomarker for patients with NSCLC

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer, a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not.

2 Jun 2010

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.

2 Jun 2010

Medical Science News

CHOC Children's receives royalty-free research license to certain StemCells' patents

SERCA2a gene therapy proves effective in people with advanced heart failure: Researchers

New pricing of $19,500 set for Illumina's individual genome sequencing service

New synthetic Petri dish harvests human embryonic stem cells

New approach to treat RA can change lives of millions of patients: Research

X+ allele of APOB gene is important risk factor of gallstone formation after gastrectomy: Research

U-M researchers one step closer to discovering why certain diseases affect specific organs

Life Technologies, DKFZ collaborate to create National High-Throughput Sequencing Center

Researchers discover relationship between DNA methylation and positioning of nucleosomes

Researchers describe chain of molecular events that increase one's risk of skin cancer

Canadian researchers: Probiotic found in breast milk reduces painful cramping in gut

Discovery provides new therapeutic target to prevent brain function loss

Meditation-based therapies benefit patients with chronic pain

Researchers develop new technique to detect cathepsin K in atherosclerosis, cancer metastasis

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Genes influence AIAA side effect in breast cancer survivors

Predictive biomarker for patients with NSCLC

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News